Tyenne Q Code: Q0238
Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Q4 2026 Medicare Payment Limit for Q0238, effective October 1, 2026: $5.581 per HCPCS billing unit, unchanged from Q3 2026. From CMS's final file.
Drug & Product Overview
About Tyenne
Tyenne is a medication aligned to the HCPCS Q Code: Q0238 for billing, pricing, and reimbursement purposes in the United States. Classified under COVID-19, it is administered via the intravenous route and manufactured by Fresenius Kabi.
Manufacturers, reach out to us to add more information.
NDC Code Information
3 NDC packages are crosswalked to Q0238. Package detail is available to logged-in subscribers.
| NDC Code | Drug | Manufacturer | Billing Units / Pkg | Package Size |
|---|---|---|---|---|
| •••••-••••-•• Log in to view | Tyenne | •••••••••••• Log in to view | •••• Log in to view | ••• •• / • •• Log in to view |
| •••••-••••-•• Log in to view | Tyenne | •••••••••••• Log in to view | •••• Log in to view | ••• •• / • •• Log in to view |
| •••••-••••-•• Log in to view | Tyenne | •••••••••••• Log in to view | •••• Log in to view | ••• •• / • •• Log in to view |
Tyenne Pricing & Reimbursement
Historical Graphing and Billing Calculator
Log in to calculate billing and reimbursement with live ASP, WAC & AWP pricing.
Login to use the calculator →Tocilizumab Biosimilar Information:
Tyenne Approval Date: March 5, 2024
| Product Name | HCPCS Code | Active Ingredient | BLA Type |
|---|---|---|---|
| Actemra | J3262 | Tocilizumab | 351(a) Originator Product |
| Tofidence | Q0234 | Tocilizumab | 351(k) Biosimilar |
| Tofidence | Q5133 | Tocilizumab | 351(k) Biosimilar |
| Tyenne | Q0238 | Tocilizumab | 351(k) Biosimilar |
| Tyenne | Q5135 | Tocilizumab | 351(k) Biosimilar |
| Avtozma | Q0237 | Tocilizumab | 351(k) Interchangeable |
| Avtozma | Q5156 | Tocilizumab | 351(k) Interchangeable |
Tyenne CPT Administration Codes
The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.
| CPT Code | Description |
|---|---|
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) |
This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →
Tyenne Clinical Information
Indications and drug classification.
This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.
Login for BuyandBill.com Analytics
Unlock deeper insights with BuyandBill’s Comparative Report!
- Compare ASP, WAC, and AWP across drugs.
- Visualize Drug Price Movement Over Time
- Tailor reports to drug class, manufacturer, or HCPCS Code.
- Compare Biosimilar and 505(b)(2) products.
Frequently Asked Questions
Is there an available Tyenne billing and coding guide?
Are there any available Tyenne patient assistance programs?
Where can I find Tyenne prescribing information?
Where can I find Tyenne side effect information?
Does billing Tyenne require JZ/JW wastage modifiers?
About BuyandBill.com:
The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.
Related Drug Codes
Explore billing, coding, and pricing for drugs related to Tyenne.
